How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Gotlib talks about fulfilling a lifelong dream of spending time with sloths by visiting Kids Saving the RainForest while on a recent trip to Costa Rica.
Take the challenge to learn what test is most likely to yield the diagnosis for a case of a 58-year-old Asian woman with history of inclusion body myositis on high-dose corticosteroids and methotrexate, noted to be hypoxic.
Can you tell what the diagnosis is for a man with a history of recurrent necrotizing pancreatitis and end-stage renal disease on intermittent hemodialysis by looking at his bone marrow biopsy?
Dr. Gotlib provides his perspective on how the groundbreaking progress in hematology achieved during 2016 has come about as well as the need to navigate the new administration to show how seriously we take hematology.
Dr. Akabutu sends Dr. Jason Gotlib a question about the November December 2016 Image Challenge.
Take the very first The Hematologist Image Challenge and try to figure out the diagnosis for a case of leukocytosis by looking at a peripheral blood smear.
Following ASH's executive committee's retreat in Havana, Cuba, Dr. Gotlib discusses lessons, challenges and opportunities for hematologists and the community, with commentary from Drs. Antonio Bencomo and Porfirio Hernández.
In this fiction piece, Dr. Gotlib provides his perspective on how hematology advances, including 2015 Year's Best selections, weave together with the compelling narratives of patients' lives.
More than 70,000 new cases of non-Hodgkin lymphoma were diagnosed in the United States during the past year. Despite the introduction of rituximab nearly two decades ago, the majority of patients with lymphoma and chronic lymphocytic leukemia (CLL) who require treatment receive cytotoxic chemotherapy. Recent advances in the understanding of the pathobiology of B-cell lymphoproliferative disorders have led to the identification of multiple therapeutic targets and the development of rational novel agents.
September-October 2017Volume 14, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology